Table 3.
Increase rates of infectious comorbidities in CVID patients with interstitial lung disease or bronchiectasis
| No lung disease (n = 1233) |
Bronchiectasis (n = 147) |
P value |
ILD (n = 138) |
P value |
|
|---|---|---|---|---|---|
| Abscess | |||||
| Deepa | 2.60% | 5.40% | .052 | 4.30% | .23 |
| Superficialb | 4.30% | 9.50% | .005 | 6.50% | .23 |
| Unspecified | 1.40% | 3.40% | .06 | 0.70% | .52 |
| GI infectionc | 14.50% | 20.40% | .06 | 12.30% | .48 |
| Hepatitis | 1.80% | 2% | .83 | 1.40% | .78 |
| Lymphadenitis | 2% | 2% | .99 | 5.10% | .03 |
| Meningitis/encephalitis | 4.90% | 4.80% | .96 | 5.80% | .63 |
| Pneumonia | 53% | 68% | .001 | 71% | < .001 |
a
Deep abscesses: Brain, dental, head and neck, inner ear, kidney, liver, lung, rectal, spleen, tonsillar, intradermal abscess, L. forearm, breast abscess, anal abscess with fistula;
b
Superficial abscesses: Abdominal wall, back and thigh, behind ear, groin, leg, lip, nostril, oral, perirectal, perianal, skin, Bartholin gland
c
GI infections: Gastrointestinal infections including infectious diarrhea, infectious enterocolitis, intestinal parasites, gastroenteritis, and small intestinal bacterial overgrowth